The University of Southampton
University of Southampton Institutional Repository

Omega-3 Fatty Acids: mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD

Omega-3 Fatty Acids: mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD
Omega-3 Fatty Acids: mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD
Non-alcoholic fatty liver disease (NAFLD) is currently considered the most common liver disease in industrialized countries, and it is estimated that it will become the most frequent indication for liver transplantation in the next decade. NAFLD may be associated with moderate (i.e. steatosis) to severe (i.e. steatohepatitis and fibrosis) liver damage and affects all age groups. Furthermore, subjects with NAFLD may be at a greater risk of other obesity-related complications later in life, and people with obesity and obesity-related complications (e.g. metabolic syndrome, type 2 diabetes and cardiovascular disease) are at increased risk of developing NAFLD. To date, there is no licensed treatment for NAFLD and therapy has been mainly centered on weight loss and increased physical activity. Unfortunately, it is often difficult for patients to adhere to the advised lifestyle changes. Therefore, based on the known pathogenesis of NAFLD, several clinical trials with different nutritional supplementation and prescribed drugs have been undertaken or are currently underway. Experimental evidence has emerged about the health benefits of omega-3 fatty acids, a group of polyunsaturated fatty acids that are important for a number of health-related functions. Omega-3 fatty acids are present in some foods (oils, nuts and seeds) that also contain omega-6 fatty acids, and the best sources of exclusively omega-3 fatty acids are oily fish, krill oil and algae. In this review, we provide a brief overview of the pathogenesis of NAFLD, and we also discuss the molecular and clinical evidence for the benefits of different omega-3 fatty acid preparations in NAFLD.
1549-781X
106-120
Nobili, V.
f50f54fe-2a6e-4763-84ef-6b7d1722e95c
Alisi, A.
c62c393b-296f-416a-aa0d-5a86a5da4378
Musso, G.
44b15c8c-8397-40b9-8986-bc2dbe6a47fd
Scorletti, E.
42bb0659-ac67-4a73-bf36-a881fe6c1563
Calder, P.C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Byrne, C.D.
1370b997-cead-4229-83a7-53301ed2a43c
Nobili, V.
f50f54fe-2a6e-4763-84ef-6b7d1722e95c
Alisi, A.
c62c393b-296f-416a-aa0d-5a86a5da4378
Musso, G.
44b15c8c-8397-40b9-8986-bc2dbe6a47fd
Scorletti, E.
42bb0659-ac67-4a73-bf36-a881fe6c1563
Calder, P.C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Byrne, C.D.
1370b997-cead-4229-83a7-53301ed2a43c

Nobili, V., Alisi, A., Musso, G., Scorletti, E., Calder, P.C. and Byrne, C.D. (2016) Omega-3 Fatty Acids: mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Critical Reviews in Clinical Laboratory Sciences, 53 (2), 106-120. (doi:10.3109/10408363.2015.1092106). (PMID:26463349)

Record type: Article

Abstract

Non-alcoholic fatty liver disease (NAFLD) is currently considered the most common liver disease in industrialized countries, and it is estimated that it will become the most frequent indication for liver transplantation in the next decade. NAFLD may be associated with moderate (i.e. steatosis) to severe (i.e. steatohepatitis and fibrosis) liver damage and affects all age groups. Furthermore, subjects with NAFLD may be at a greater risk of other obesity-related complications later in life, and people with obesity and obesity-related complications (e.g. metabolic syndrome, type 2 diabetes and cardiovascular disease) are at increased risk of developing NAFLD. To date, there is no licensed treatment for NAFLD and therapy has been mainly centered on weight loss and increased physical activity. Unfortunately, it is often difficult for patients to adhere to the advised lifestyle changes. Therefore, based on the known pathogenesis of NAFLD, several clinical trials with different nutritional supplementation and prescribed drugs have been undertaken or are currently underway. Experimental evidence has emerged about the health benefits of omega-3 fatty acids, a group of polyunsaturated fatty acids that are important for a number of health-related functions. Omega-3 fatty acids are present in some foods (oils, nuts and seeds) that also contain omega-6 fatty acids, and the best sources of exclusively omega-3 fatty acids are oily fish, krill oil and algae. In this review, we provide a brief overview of the pathogenesis of NAFLD, and we also discuss the molecular and clinical evidence for the benefits of different omega-3 fatty acid preparations in NAFLD.

Text
Critical Reviews in Clinical Laboratory Sciences_ Aug 2015_Rev1 - Accepted Manuscript
Download (438kB)

More information

Accepted/In Press date: 15 August 2015
e-pub ahead of print date: 14 October 2015
Published date: July 2016
Organisations: Human Development & Health

Identifiers

Local EPrints ID: 381269
URI: http://eprints.soton.ac.uk/id/eprint/381269
ISSN: 1549-781X
PURE UUID: ee57f59c-e029-4cf4-b593-043c4a6d7f15
ORCID for P.C. Calder: ORCID iD orcid.org/0000-0002-6038-710X
ORCID for C.D. Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 25 Sep 2015 15:14
Last modified: 11 Mar 2021 02:35

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×